Anakinra in Still’s disease: a profile of its use

The EU indication for anakinra has been extended to include Still’s disease, a serious rare inflammatory disorder of unknown aetiology that comprises adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA). As activated interleukin-1 pathways are associated with the syst...

Descripción completa

Detalles Bibliográficos
Autor principal: Lyseng-Williamson, Katherine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Adis Drug Q&A
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267530/
https://www.ncbi.nlm.nih.gov/pubmed/30546251
http://dx.doi.org/10.1007/s40267-018-0572-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267530/
https://www.ncbi.nlm.nih.gov/pubmed/30546251
http://dx.doi.org/10.1007/s40267-018-0572-5

Ejemplares similares